Boehringer Ingelheim Brings Innovative Therapies to the 8th CIIE

Leading global biopharmaceutical company Boehringer Ingelheim is showcasing its innovation blueprint aimed at accelerating pipeline research and development and fostering quality growth in China at its 500-square-meter innovation-themed booth at the China International Import Expo.

Under the theme "Innovation and Collaboration," the company is displaying several innovative therapies, including three that have received Breakthrough Therapy Designations in China. These therapies target significant health issues such as lung cancer, pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis (MASH).

A focal point of the booth is an art installation designed to draw visitors' attention. This installation utilizes plants to represent diseased lungs: some appear dried and hardened due to fibrosis, while others exhibit bronchiectasis as a result of chronic inflammation or infection.

At the heart of the installation is a vibrant red plant, symbolizing a healthy lung, full of life. This striking visual contrast effectively draws attention and raises awareness about the importance of lung health.

Additionally, the installation highlights Jascayd, a treatment for idiopathic pulmonary fibrosis, which is the first therapy of its kind approved in a decade, providing a new treatment option for patients in China. A second indication for this drug, progressive pulmonary fibrosis, is currently undergoing priority review in China.

This year also marks the German pharmaceutical company's 30th anniversary in China.

"The scale of our innovative achievements at this year's booth surpassed previous years, with a total of seven newly approved/launched products across Human Pharma and Animal Health, focusing on the diverse needs of the silver-haired population and pets," said Jonathan Chin, general manager of Boehringer Ingelheim China's Human Pharma Business.

The lung cancer medicine Hernexeos is also under the spotlight, which is the world's first and only approved oral HER2 tyrosine kinase inhibitor for treating HER2-mutant Non-Small Cell Lung Cancer.

Boehringer Ingelheim has participated in the CIIE for seven consecutive years, viewing the expo as a valuable platform for fostering open collaboration. During this year's event, the company established new partnerships with hospitals, academic societies, and patient organizations aimed at promoting disease education, empowering patients, and advancing clinical research.

Using the CIIE as a crucial platform to speed up new product introduction and deepen partnerships with hospitals, academic societies, and patient organizations, Boehringer Ingelheim is speeding up the R&D process in the next few years.

Since the launch of its "China Key" strategy in 2019, China has been fully integrated into its global early-stage clinical development projects, with China's parallel research programs with the rest of the world to accelerate the development and approval.

"We have brought the latest achievements of the 'China Key' project to CIIE every year, and many of these exhibits have successfully turned into commercial products, accelerating their market entry and benefiting patients," Chin said.

Over the next five years, R&D investment in Human Pharma in China will exceed 3.5 billion yuan (US$ 491 million).

"The pipeline will focus on metabolism, inflammation, eye health, and oncology, and we anticipate achieving around 25 registration approvals by 2030," said Chin.

In the animal health field, it has brought several industry-leading innovations and solutions, addressing key disease prevention and management needs.

Highlighted products include the new Frontpro for treating flea and tick problems, Ingelvac® PRRS MLV for porcine reproductive and respiratory syndrome, and Semintra for chronic kidney disease in cats.

Senvelgo, a first-in-class once-daily oral liquid prescription therapy for feline diabetes, is currently under regulatory review.

Their debut underscores Boehringer Ingelheim's ongoing commitment to innovation in animal health, its deep engagement in the local market, and its proactive response to the growing demand among Chinese pet owners for advanced health management solutions.